Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Classic Hodgkin Lymphoma — Treatment

First-line Second-line SECOND-LINE Classic Hodgkin lymphoma Early-stage favorable Early-stage unfavorable Advanced-stage Relapsed / refractory Combined-modality ABVD ×2 + ISRT HD10 ↗ Combined-modality ABVD ×4 + ISRT HD11 ↗ BV-based Brentuximab + AVD ECHELON-1 ↗ IO-based Nivolumab + AVD S1826 ↗ Salvage Salvage chemo → autologous SCT chemosensitive relapse Maintenance Brentuximab vedotin AETHERA ↗ IO Nivolumab / pembrolizumab KEYNOTE-204 ↗